Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

F18 FBPA · F18

Radiopharmaceutical · Acts on L-type amino acid transporter 1 (SLC7A5) · developed by Heron Neutron Medical

Phase 1/2 Most advanced trial
HRTX Developer
1 Registered trials

What is F18 FBPA?

F18 FBPA (4-borono-2-[18F]fluoro-L-phenylalanine) is a radiolabeled phenylalanine analog used in positron emission tomography. Its uptake is mainly facilitated by the L-type amino acid transporter 1 (LAT1), which is commonly overexpressed in malignant tumors, allowing preferential accumulation in tumor tissue for tumor imaging in solid tumors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
F18
Drug type
Radiopharmaceutical
Targets
L-type amino acid transporter 1 (SLC7A5)
Mechanism
Acts on L-type amino acid transporter 1 (SLC7A5)
Therapy area
Oncology
Developer
Heron Neutron Medical Corp. (HRTX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07691775 Phase 1/2 Solid Tumor Recruiting HRTX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Solid Tumor

Other drugs acting on SLC7A5

More from Heron Neutron Medical

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the HRTX page.

Follow HRTX, the company behind F18 FBPA

See HRTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

HRTX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.